Entia Biosciences, Inc. - FORM 10-Q - XML - IDEA: XBRL DOCUMENT - November 15, 2012

Attached files
FileFilename
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R27.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R30.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R9.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R20.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R38.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R10.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R5.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R26.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R21.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R34.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R16.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R14.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R13.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R15.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R19.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R23.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R11.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R12.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R4.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R18.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R1.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R17.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R3.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R7.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R24.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R36.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R22.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R35.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R6.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R2.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R40.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R32.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R8.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R31.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R28.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R29.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R43.htm
EXCEL - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.Financial_Report.xls
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R37.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R42.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R25.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R33.htm
XML - IDEA: XBRL DOCUMENT - Entia Biosciences, Inc.R39.htm
EX-32.2 - EXHIBIT 32.2 - Entia Biosciences, Inc.ex32_2apg.htm
EX-32.1 - EXHIBIT 32.1 - Entia Biosciences, Inc.ex32_1apg.htm
EX-31.2 - EXHIBIT 31.2 - Entia Biosciences, Inc.ex31_2apg.htm
EX-31.1 - EXHIBIT 31.1 - Entia Biosciences, Inc.ex31_1apg.htm
10-Q - ERGO 10-Q 09/30/12 - Entia Biosciences, Inc.ergo10q_093012apg.htm
v2.4.0.6
NOTE 9 - STOCKHOLDERS' EQUITY (DEFICIT) (Details Narrative) (USD $)
 3 Months Ended
Sep. 30, 2012
Jun. 30, 2012
Mar. 31, 2012
Jan. 01, 2012
May 26, 2011
Sep. 17, 2010
Notes to Financial Statements            
Shares of preferred stock designated as Series A preferred stock         350,000  
Series A preferred stock par value         $ 0.001  
Liquidation preference per Series A preferred share         $ 5  
Series A preferred stock issued for cash 4,600 12,800        
Cash proceeds from issuance of Series A preferred shares $ 23,000 $ 64,000        
Non-cash deemed dividend on the Series A preferred stock   21,139        
Series A preferred stock issued in exchange for cancellation of note payable   1,000        
Note payable amount cancelled in exchange for Series A preferred shares   10,000        
Series A preferred stock issued for consulting services   7,000        
Value of Series A preferred shares issued in exchange for consutling services   35,000        
Series A preferred stock issued     19,000      
Value of Series A preferred stock issued     95,000      
Common stock issued in exchange for license agreement   50,000        
Value of common stock issued in exchange for license agreement   50,000        
Common stock issued to employees as compensation     666      
Number of employees who received common stock as compensation     2      
Fair market value of common stock issued to employees as compensation     400      
Common shares reserved for the 2012 Stock Incentive Plan           1,500,000
Annual increase in reserved shares of the 2010 Stock Incentive Plan       50,000    
Minimum expected volatility assumption for Black-Scholes option pricing     183.17%      
Maximum expected volatility assumption for Black-Scholes option pricing     187.30%      
Minimum risk free rate assumption for Black-Scholes option pricing     1.27%      
Maximum risk free rate assumption for Black-Scholes option pricing     2.80%      
Minimum expected life assumption for Black-Scholes option pricing model     4 years      
Maximum expected life assumption for Black-Scholes option pricing model     10 years      
Authorized shares underlying options available for granting under the 2010 Stock Incentive Plan 123,513          
Shares available for purchase from exercisable options 807,281          
Remaining contractual term of the options to purchase shares 10 years          
The weighted average fair value of stock options granted $ 0.53          
Weighted average exercise price of stock options granted and exercisable $ 0.56          
Aggregate fair value of options vested 170,342          
Unvested options 263,227          
Options forfeited 20,000          
Value of options forfeited 7,655          
Number of options exercised 0          
Number of options expired 0          
Aggregate intrinsic value of outstanding stock options 762,430          
Aggregate intrinsic value of exercisable stock options 512,137          
Total unrecognized compensation cost related to unvested stock options 263,227          
Weighted average period to recognize compensation cost related to unvested stock options (in years) 7 years          
Number of common shares underlying the warrants issued for consulting service agreement   30,496 152      
Number of common shares underlying the warrants issued under debt agreements to raise capital   308,750        
Minimum warrant exercise price   $ 0.45        
Maximum warrant exercise price   $ 5.00        
Average term of warrants (in years)   5 years 9 months        
Exercise price of warrants     $ 5.00      
Term of warrants (in years)     7 years      
Special conversion price for options and warrants if holder commits to exercising by July 31, 2012 $ 0.40          
Warrants exercised at special price 222,500          
Proceeds from warrants exercised at special price 89,000          
Cash received from exercise of warrants at special price 30,000          
Warrants exercised at special price in exchange for short term notes with interest $ 59,000          
Term of promissory notes 6 months          
Minimum interest rate of short term notes issued for warrant exercise at special price 6.00%          
Maximum interest rate of short term notes issued for warrant exercise at special price 20.00%          

User Contributions:

Comment about this document or add new information about this topic:

CAPTCHA


This web site and associated pages are not associated with, endorsed by, or sponsored by Entia Biosciences, Inc. and has no official or unofficial affiliation with Entia Biosciences, Inc.


Based on public records. Inadvertent errors are possible.
Faqs.org does not guarantee the accuracy or timeliness of any information on this site.  Use at your own risk. This website is not associated with the SEC

Some parts © 2013 Advameg, Inc.